The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•28 February 2026•

1 min read

BeOne Medicines (ONC) Maintains 'Strong Buy' Rating Amid Robust Brukinsa Sales and FDA Catalysts

Key Facts

1Brukinsa sales grew 49% YoY to reach $3.93B in 2025.

2A 12-month price target of $410 per share was set with a 'strong buy' rating.

BeOne Medicines (ONC) continues to demonstrate strong market momentum, supported by a 'Strong Buy' rating and a 12-month price target of $410 per share. The company's flagship drug, Brukinsa, reported a stellar 49% year-over-year growth in sales, reaching $3.93 billion in 2025. This performance solidifies the firm's leadership in the Chronic Lymphocytic Leukemia (CLL) market as it approaches a critical profitability inflection point. Looking ahead to 2026, investors are focused on several high-impact catalysts, including potential FDA approvals for Sonrotoclax and BTK-CDAC. Despite a modest miss in its 2026 guidance, the robust pipeline and core product growth suggest a positive long-term outlook for the biotech firm.